Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 2952-2962

  Hourdequin, K C ^a,b,c   Schpero, W L ^b   McKenna, D R ^b,c   Piazik, B L ^b,d   Larson, R J ^b,c,e  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Dosing; Obesity; Survival; Toxic effect

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; LOMUSTINE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILE DUCT CANCER; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; COLON CANCER; DIARRHEA; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; GALLBLADDER CANCER; GASTROINTESTINAL CARCINOMA; HUMAN; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; METASTATIC COLORECTAL CANCER; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OBESITY; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

CHEMOTHERAPY; DOSING; OBESITY; SURVIVAL; TOXIC EFFECT;

ANTINEOPLASTIC AGENTS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; HUMANS; NEOPLASMS; OBESITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84888801845     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt294     Document Type: Review

References (64)

1. Flegal KM, Carroll MD, Ogden CL et al Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
2. Mick R, Ratain MJ. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst 1993; 85: 217-223.
3. EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee. Eur J Cancer Clin Oncol 1985; 21: 1005-1007.
4. Freireich EJ, Gehan EA, Rall DP et al Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219-244.
5. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998; 16: 2297-2298.
6. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958; 18: 853-856.
7. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165: 1267-1273.
8. Lyman GH. Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines. J Oncol Pract 2011; 7: 17-18.
9. Smith TJ, Desch CE. Neutropenia-wise and pound-foolish: safe and effective chemotherapy in massively obese patients. South Med J 1991; 84: 883-885.
10. Griggs JJ, Culakova E, Sorbero MES et al Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 2007; 25: 277-284.
11. Grigg A, Harun MH, Szer J. Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. Leuk Lymphoma 1997; 25: 487-491.
12. Field KM, Kosmider S, Jefford M et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008; 4: 108-113.
13. Schwartz J, Toste B, Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. Gynecol Oncol 2009; 114: 53-56.
14. Georgiadis MS, Steinberg SM, Hankins LA et al. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 1995; 87:361-366.
15. Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer 2007; 43: 544-548.
16. Wright JD, Tian C, Mutch DG et al. Carboplatin dosing in obese women with ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 2008; 109:353-358.
17. Banerji U, Ashley S, Coward J et al. The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer 2006; 54: 371-377.
18. Han YW, Yu ZH, Wen SY et al. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res Treat 2012; 131:483-490.
19. Shitara K, Matsuo K, Oze I et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol 2011; 68: 301-307.
20. Efstathiou JA, Bae K, Shipley WU et al Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer 2007; 110:2691-2699.
21. Lu Y, Ma H, Malone KE et al. Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol 2011; 29: 3358-3365.
22. Meyerhardt JA, Catalano PJ, Haller DG et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003; 98: 484-495.
23. Boyd NF, Campbell JE, Germanson T et al. Body weight and prognosis in breast cancer. J Natl Cancer Inst 1981; 67: 785-789.
24. Newman SC, Lees AW, Jenkins HJ. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol 1997; 26:484-490.
25. Zhang M, Xie X, Lee AH et al. Body mass index in relation to ovarian cancer survival. Cancer Epidemiol Biomarkers Prev 2005; 14: 1307-1310.
26. Pavelka JC, Brown RS, Karlan BY et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer 2006; 107: 1520-1524.
27. Litton JK, Gonzalez-Angulo AM, Warneke CL et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 2008; 26: 4072-4077.
28. de Azambuja E, McCaskill-Stevens W, Francis P et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 2010; 119: 145-153.
29. Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011; 77: 221-240.
30. Wood WC, Budman DR, Korzun AH et al Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. [Erratum appears in N Engl J Med 1994 Jul 14;331(2):139]. N Engl J Med 1994; 330:1253-1259.
31. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-15.
32. Kwak LW, Halpern J, Olshen RA et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-977.
33. Arriagada R, Le Chevalier T, Pignon JP et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329:1848-1852.
34. Budman DR, Berry DA, Cirrincione CT et al Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-1211.
35. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
36. Liberati A, Altman DG, TetzlaffJ et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151:W65-W94.
37. Kuribayashi T, Kondo M, Yorozu A et al. Feasibility of CHOP chemotherapy-with special reference to age, diabetes mellitus, liver cirrhosis and obesity. Nihon Gan Chiryo Gakkai Shi 1989; 24: 109-116.
38. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52:377-384.
39. Common Terminology Criteria for Adverse Events (CTCAE) v 3.0. Bethesda, MD:National Cancer Institute, NIH publication No. 03-5410 2006.
40. Colleoni M, Li SG, Gelber RD et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366: 1108-1110.
41. Farker K, Merkel U, Wedding U et al. Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients:original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. Int J Clin Pharmacol Ther 2006; 44: 31-37.
42. Meloni G, Proia A, Capria S et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 2001; 28:365-367.
43. Meyerhardt JA, Tepper JE, Niedzwiecki D et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from intergroup trial 0114. J Clin Oncol 2004; 22:648-657.
44. Miya T, Goya T, Yanagida O et al. The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide. Cancer Chemother Pharmacol 1998; 42: 386-390.
45. Poikonen P, Blomqvist C, Joensuu H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol 2001; 40: 67-71.
46. Rosner GL, Hargis JB, Hollis DR et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14: 3000-3008.
47. Jones JA, Fayad LE, Elting LS et al. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-hodgkin lymphoma. Leuk Lymphoma 2010; 51: 1649-1657.
48. Barrett SV, Paul J, Hay A et al. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol 2008; 19: 898-902.
49. Chambers P, Daniels SH, Thompson LC et al. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 2012; 23: 748-753.
50. Hunter RJ, Navo MA, Thaker PH et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78.
51. Griggs JJ, Mangu PB, Anderson H et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2012; 30: 1553-1561.
52. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 1990; 82: 323-325.
53. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-2611.
54. Baker SD, Verweij J, Rowinsky EK et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002; 94: 1883-1888.
55. de Jongh FE, Verweij J, Loos WJ et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19: 3733-3739.
56. Mathijssen RHJ, Verweij J, de Jonge MJA et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20:81-87.
57. Loos WJ, Gelderblom H, Sparreboom A et al. Inter-and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 2000; 6: 2685-2689.
58. Etienne MC, Chatelut E, Pivot X et al Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 1998; 34: 92-97.
59. Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 2010; 41:458-463.
60. Capitain O, Asevoaia A, Boisdron-Celle M et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 2012; 11: 263-267.
61. Gamelin E, Delva R, Jacob J et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2099-2105.
62. Joerger M, KraffS, Huitema AD et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51:607-617.
63. Salas S, Mercier C, Ciccolini J et al. Therapeutic drug monitoring for dose individualization of cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit 2006; 28:532-539.
64. Saleem M, Dimeski G, Kirkpatrick CM et al. Target concentration intervention in oncology: where are we at? Ther Drug Monit 2012; 34: 257-265.